ReviewClinical kidney journal2025
Potential and pitfalls of measuring circulating anti-nephrin autoantibodies in glomerular diseases.
Review in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current status and research hotspots of pediatric nephrotic syndrome: a bibliometric analysis (2011-2025).Frontiers in pediatrics · 2026Pooled it
- Anti-nephrin antibodies in pediatric nephrotic syndrome: a new paradigm.Pediatric nephrology (Berlin, Germany) · 2026Review
- Association between anti-nephrin autoantibodies and disease activity in minimal change disease.Annals of medicine · 2026Article
- Immune dysregulation in pediatric cancer-associated nephrotic syndrome: current insights.Pediatric nephrology (Berlin, Germany) · 2026Review
- A case of anti-nephrin antibody-positive, steroid-dependent nephrotic syndrome with successful discontinuation of immunosuppressants following rituximab.Oxford medical case reports · 2026Article
- Anti-nephrin autoantibodies in post-transplant recurrent focal segmental glomerulosclerosis: diagnostic advances and future directions.Clinical and experimental nephrology · 2026Review
- Nephrotic Syndrome: Current Management.Indian journal of pediatrics · 2026Review
- Application of the nephrotoxic serum nephritis model in glomerulonephritis research.Molecular medicine (Cambridge, Mass.) · 2026Review
- Autoantibodies against nephrin and podocin are associated with disease severity and steroid dependence in adult-onset nephrotic syndrome.Scientific reports · 2026Article
- Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study.Transplantation direct · 2026Article
- Immune podocyte injury in autoimmune glomerular diseases.Frontiers in immunology · 2026Review
- Podocytopathies.Nature reviews. Disease primers · 2025Review
- Serum Factors in Primary Podocytopathies.Antibodies (Basel, Switzerland) · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have identified autoantibodies targeting the podocyte protein nephrin in patients with primary podocytopathies such as minimal change disease, primary focal segmental glomerulosclerosis (FSGS), post-transplant recurrent FSGS and childhood idiopathic nephrotic syndrome. These antibodies bind nephrin and directly influence nephrin downstream signaling, with immense effect on the podocytes' cellular structure and function, substantially changing our understanding of antibody-mediated podocytopathies and disease classification. Their presence correlates with disease activity and holds great potential as a novel biomarker of anti-nephrin-associated podocytopathy. However, the detection of these potentially low-titre autoantibodies has proven challenging. In this review, we highlight and explain distinct detection methodologies with their advantages and disadvantages and discuss the potential of anti-nephrin autoantibodies as a novel biomarker in nephrotic syndrome for diagnosis, prognostication and therapeutic guidance in patients with nephrotic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.